Mortality
Overall mortality was 35.6% (50%, 30.2% and 36% for group 1, 2 and
3, respectively) without significant differences between groups
(Log-rank p=0.398)(figure 4B). Causes of death were classified as
arrhythmic/sudden death in 5 cases (8.8%), advanced heart failure in 27
cases (47.4%), non-cardiac deaths in 17 cases (29.8%) and unknown
cause in 8 cases (14%). VT recurrence was not associated with
mortality/cardiac transplantation (mortality/transplant 51% for
patients with VT recurrence vs. 38.9% for patients without VT
recurrence, Log-rank p=0.253). However, patients with baseline 1 VT
morphology (group 2) and activation mapping during the procedure had
significantly lower mortality during follow-up (19.2% vs 38.8%,
Log-rank p=0.039)(figure 4A). In multivariate analysis the only
independent predictor of mortality was baseline LVEF<30% (HR
2.43 CI 95% 1.45-4.07, p<0.001)(table 4).